Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)
about
HnRNP A1/A2 and SF2/ASF regulate alternative splicing of interferon regulatory factor-3 and affect immunomodulatory functions in human non-small cell lung cancer cellsThe emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsThe roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunityNF-κB, the first quarter-century: remarkable progress and outstanding questionsIL-17 family: cytokines, receptors and signalingCell type- and stimulus-specific mechanisms for post-transcriptional control of neutrophil chemokine gene expressionThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testingEffect of IL-17 receptor A blockade with brodalumab in inflammatory diseasesDifferential Gene Expression Profiles and Selected Cytokine Protein Analysis of Mediastinal Lymph Nodes of Horses with Chronic Recurrent Airway Obstruction (RAO) Support an Interleukin-17 Immune ResponseNegative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP25NADPH oxidase mediates synergistic effects of IL-17 and TNF-α on CXCL1 expression by epithelial cells after lung ischemia-reperfusion.IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation.Interleukin 17A Promotes Lymphocytes Adhesion and Induces CCL2 and CXCL1 Release from Brain Endothelial Cells.IL-17A mediates a selective gene expression profile in asthmatic human airway smooth muscle cells.The adaptor TRAF5 limits the differentiation of inflammatory CD4(+) T cells by antagonizing signaling via the receptor for IL-6.TPL2 mediates autoimmune inflammation through activation of the TAK1 axis of IL-17 signaling.The differential regulation of human ACT1 isoforms by Hsp90 in IL-17 signalingPromotion of lung tumor growth by interleukin-17Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription.AZD5363 Inhibits Inflammatory Synergy between Interleukin-17 and Insulin/Insulin-Like Growth Factor 1The anaphase-promoting complex protein 5 (AnapC5) associates with A20 and inhibits IL-17-mediated signal transduction.IL-17 attenuates degradation of ARE-mRNAs by changing the cooperation between AU-binding proteins and microRNA16.Local IL-17A potentiates early neutrophil recruitment to the respiratory tract during severe RSV infectionTherapeutic administration of the chemokine CXCL1/KC abrogates autoimmune inflammatory heart diseaseTRAF4-SMURF2-mediated DAZAP2 degradation is critical for IL-25 signaling and allergic airway inflammation.CIKS/DDX3X interaction controls the stability of the Zc3h12a mRNA induced by IL-17Human colon carcinogenesis is associated with increased interleukin-17-driven inflammatory responses.Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis.The airway microbiome in patients with severe asthma: Associations with disease features and severity.The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblastsBasic biology and role of interleukin-17 in immunity and inflammationCIKS/Act1-mediated signaling by IL-17 cytokines in context: implications for how a CIKS gene variant may predispose to psoriasis.MCPIP1 Endoribonuclease Activity Negatively Regulates Interleukin-17-Mediated Signaling and Inflammation.A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis.Control of IL-17 receptor signaling and tissue inflammation by the p38α-MKP-1 signaling axis in a mouse model of multiple sclerosisTRAF6-dependent Act1 phosphorylation by the IκB kinase-related kinases suppresses interleukin-17-induced NF-κB activationDeleterious effect of the IL-23/IL-17A axis and γδT cells on left ventricular remodeling after myocardial infarction.CD4(+) T-cell subsets and host defense in the lungCutting edge: TNF receptor-associated factor 4 restricts IL-17-mediated pathology and signaling processes.Diversity in sequence-dependent control of GRO chemokine mRNA half-life
P2860
Q21559659-BF55D05D-5310-4F2A-9017-E0D1C0BC03D0Q24623195-A08028CC-E221-483B-84EB-FE2D8405C623Q26750673-EE913A4A-9FB0-4604-9194-4695A6E50BDCQ26822516-0A7DFD31-325A-456E-876D-C1BBE8AADDD9Q26860251-3A73CEE5-612A-4856-80E9-8E78FCAFCD70Q27004287-438C650D-0F27-4746-84CA-334F8DD2C0D8Q27687800-9CA275BE-41CF-4D59-9912-FAAF5FAB828AQ28076496-9BBF777F-30A8-40A4-8C00-5A93032FD743Q28393712-E36E50C7-0226-4FA5-AAC4-79A3DC20FC8AQ28588560-D468F5FA-D0DD-4C51-8E09-4C2BB79D4E1CQ30408739-105F2601-663D-42F1-A136-3A71911821D6Q30515381-08494AEA-199E-47BB-9B17-F0DCF7476DE6Q33755098-9D214673-BB0E-4A37-8A80-EAA65C265E64Q33799505-BE933EF5-8C7E-44EE-9F7B-0109BDEE94D6Q33940420-22A186A4-AF9A-4795-B1D0-887AA715C69BQ33964282-44DA977B-430F-4912-9779-76DED405BD2EQ33992530-CC9E9F16-4E64-45BB-A8A6-6FC01A5524A2Q34201267-B301F305-B6D7-4030-9144-C8872FAE665AQ34322605-2472B95A-9BB4-46E2-9709-2516A944AEDFQ34595624-4E967F0A-3866-4B32-8B63-5BCF4EDD0215Q34906387-3DF751BB-E4E3-4C89-932D-BB3177BEDD50Q35004498-F2CC3ED4-96DD-43EA-BA12-8EEF7E0B5AF2Q35032594-3D2484E9-FE6E-4122-B200-B38A72C6C17DQ35107814-8248C04E-42C2-4072-A01B-C6192946A56CQ35198294-D2FF2689-7F53-481C-9F7D-498D1AF39D93Q35205523-DF1CAC66-3C6D-4CC0-A159-C008E6F34101Q35209789-B098505E-A8A4-476F-9F33-AF2E2B1B6A3DQ35522947-B5F70FF1-720E-47E5-BE0B-DA04F80CC883Q35721479-F2A5D19F-7218-4F0D-8F0F-B96D6F585F0CQ35770438-EB3C811E-C9FA-4A8C-8DC3-7D870EFE699AQ35932948-DFE55957-128F-47C9-AFCD-E0186315FC89Q36016658-FC3804E5-6CAC-4E81-84BC-91246333FCC5Q36073357-40F89E3C-5CE4-45E3-A957-C2092D5A15C3Q36080701-820296B7-A5F8-40D7-AA37-9013459081E3Q36267838-0EFC38AD-15D2-4847-B43A-D951BE4F4A0AQ36277273-B44C739E-8CBD-4EF8-AF87-AED5E4A3F870Q36522680-80A56BCB-8726-478A-9C1A-10FCB84E7CDAQ36622318-CD25EE9E-4431-41D8-989E-46D86C795985Q36664237-89D0A32E-E236-4BFA-8C33-FC1949904EDBQ36850466-55E8A847-CEB0-491B-A724-65521C4AD697
P2860
Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@ast
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@en
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@en-gb
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@nl
type
label
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@ast
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@en
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@en-gb
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@nl
prefLabel
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@ast
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@en
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@en-gb
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@nl
P2093
P2860
P921
P356
P1433
P1476
Treatment with IL-17 prolongs ...... ng-regulatory factor SF2 (ASF)
@en
P2093
Dongxu Sun
Katarzyna Bulek
Michael Novotny
Thomas Hamilton
Xiaoxia Li
P2860
P304
P356
10.1038/NI.2081
P407
P577
2011-09-01T00:00:00Z